Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey
AIM: To report the real-life experience and clinical results of intravitreal ranibizumab injections to neovascular age-related macular degeneration (nAMD) in a single institution in Turkey. METHODS: A total of 101 eyes of 89 patients with nAMD treated with intravitreal ranibizumab injection, follow...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2018-02-01
|
Series: | International Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.cn/en_publish/2018/2/20180215.pdf |
id |
doaj-a2e30908c55c4071995412624fa8952a |
---|---|
record_format |
Article |
spelling |
doaj-a2e30908c55c4071995412624fa8952a2020-11-24T22:21:27ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982018-02-0111226727310.18240/ijo.2018.02.15Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from TurkeyZafer Cebeci0Yusuf Cem Yilmaz1Nur Kir2Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34104, TurkeyDepartment of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34104, TurkeyDepartment of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34104, TurkeyAIM: To report the real-life experience and clinical results of intravitreal ranibizumab injections to neovascular age-related macular degeneration (nAMD) in a single institution in Turkey. METHODS: A total of 101 eyes of 89 patients with nAMD treated with intravitreal ranibizumab injection, followed up for at least 24mo between 2009 and June 2014, which were evaluated retrospectively. A pro re nata (PRN) treatment protocol was performed after the patients had received three, monthly loading injections. Best corrected visual acuity (BCVA) and central macular thickness measurements were evaluated at baseline and 3, 6, 12, 18, and 24mo. Number of injections and visits were also recorded. RESULTS: Of the 89 patients, 34 (38.2%) were male and 55 (61.8%) were female and the mean age was 74.0±9.5 (52-91)y. The mean follow-up period was 24.82±4.4 (24-29)mo. Mean number of visits was 8.4±1.12 (7-12) in the first year and 6.6±1.33 (4-12) in the second year. The mean number of injections was 5.8±1.6 (3-10) and 4.2±2.2 (0-9) in the first and second year, respectively. The mean BCVA was 59±15.8 letters at baseline by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean BCVA at 3, 12, and 24mo was 70.3±15.9, 67.9±14.3 and 67.3±16.9 letters, respectively. Improvement in visual acuity for each of the visits from baseline was found to be statistically significant (P<0.01). Visual acuity in 9 eyes at month 3, 7 eyes at month 12, and 13 eyes at month 24 did not change. The mean central macular thickness (CMT) was 437.99±164.78 μm at baseline. The mean CMT was 348.05±138.47 μm, 349.27±139.79 μm, and 344.13±146.30 μm at months 3, 12, and 24, respectively. The decrease in CMT for each of the visits from baseline was found to be statistically significant (P<0.01). CONCLUSION: Anatomical and functional achievement are obtained in our study, but the mean number of injections and visits are found to be lower than the findings reported in randomized controlled clinical trials in the literature. However, the mean number of injections and visits in our study are compatible with the findings reported in real-life experience studies in the literature.http://www.ijo.cn/en_publish/2018/2/20180215.pdf273age-related macular degenerationanti-vascular endothelial growth factorvisual acuityranibizumabretinaoptical coherence tomography |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zafer Cebeci Yusuf Cem Yilmaz Nur Kir |
spellingShingle |
Zafer Cebeci Yusuf Cem Yilmaz Nur Kir Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey International Journal of Ophthalmology 273 age-related macular degeneration anti-vascular endothelial growth factor visual acuity ranibizumab retina optical coherence tomography |
author_facet |
Zafer Cebeci Yusuf Cem Yilmaz Nur Kir |
author_sort |
Zafer Cebeci |
title |
Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey |
title_short |
Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey |
title_full |
Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey |
title_fullStr |
Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey |
title_full_unstemmed |
Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey |
title_sort |
real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from turkey |
publisher |
Press of International Journal of Ophthalmology (IJO PRESS) |
series |
International Journal of Ophthalmology |
issn |
2222-3959 2227-4898 |
publishDate |
2018-02-01 |
description |
AIM: To report the real-life experience and clinical results of intravitreal ranibizumab injections to neovascular age-related macular degeneration (nAMD) in a single institution in Turkey.
METHODS: A total of 101 eyes of 89 patients with nAMD treated with intravitreal ranibizumab injection, followed up for at least 24mo between 2009 and June 2014, which were evaluated retrospectively. A pro re nata (PRN) treatment protocol was performed after the patients had received three, monthly loading injections. Best corrected visual acuity (BCVA) and central macular thickness measurements were evaluated at baseline and 3, 6, 12, 18, and 24mo. Number of injections and visits were also recorded.
RESULTS: Of the 89 patients, 34 (38.2%) were male and 55 (61.8%) were female and the mean age was 74.0±9.5 (52-91)y. The mean follow-up period was 24.82±4.4 (24-29)mo. Mean number of visits was 8.4±1.12 (7-12) in the first year and 6.6±1.33 (4-12) in the second year. The mean number of injections was 5.8±1.6 (3-10) and 4.2±2.2 (0-9) in the first and second year, respectively. The mean BCVA was 59±15.8 letters at baseline by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean BCVA at 3, 12, and 24mo was 70.3±15.9, 67.9±14.3 and 67.3±16.9 letters, respectively. Improvement in visual acuity for each of the visits from baseline was found to be statistically significant (P<0.01). Visual acuity in 9 eyes at month 3, 7 eyes at month 12, and 13 eyes at month 24 did not change. The mean central macular thickness (CMT) was 437.99±164.78 μm at baseline. The mean CMT was 348.05±138.47 μm, 349.27±139.79 μm, and 344.13±146.30 μm at months 3, 12, and 24, respectively. The decrease in CMT for each of the visits from baseline was found to be statistically significant (P<0.01).
CONCLUSION: Anatomical and functional achievement are obtained in our study, but the mean number of injections and visits are found to be lower than the findings reported in randomized controlled clinical trials in the literature. However, the mean number of injections and visits in our study are compatible with the findings reported in real-life experience studies in the literature. |
topic |
273 age-related macular degeneration anti-vascular endothelial growth factor visual acuity ranibizumab retina optical coherence tomography |
url |
http://www.ijo.cn/en_publish/2018/2/20180215.pdf |
work_keys_str_mv |
AT zafercebeci reallifeexperienceofranibizumabtherapyforneovascularagerelatedmaculardegenerationfromturkey AT yusufcemyilmaz reallifeexperienceofranibizumabtherapyforneovascularagerelatedmaculardegenerationfromturkey AT nurkir reallifeexperienceofranibizumabtherapyforneovascularagerelatedmaculardegenerationfromturkey |
_version_ |
1725771142651707392 |